Current Report Filing (8-k)
February 18 2014 - 4:36PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
February
18, 2014
|
Date
of Report (Date of earliest event reported)
|
NPS
PHARMACEUTICALS, INC.
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
0-23272
|
87-0439579
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification Number)
|
550 Hills Drive, 3rd Floor
|
Bedminster, NJ 07921
|
(Address of principal executive offices)
|
|
(908) 450-5300
|
|
(Registrant’s telephone number, including area code)
|
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On February 18, 2014, NPS Pharmaceuticals, Inc. issued a press release
announcing its operating results for the fourth quarter and year ended
December 31, 2013. The text of the press release is furnished as
Exhibit 99.1 to this Form 8-K.
The information in Item 2.02 of this Form 8-K and the Exhibit 99.1
attached hereto shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set forth
by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release issued by NPS Pharmaceuticals, Inc. on February 18,
2014
|
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date:
|
February 18, 2014
|
NPS PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/ Jill Thompson
|
|
|
|
Jill Thompson
|
|
|
|
Acting General Counsel and Secretary
|
Nps (NASDAQ:NPSP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Nps (NASDAQ:NPSP)
Historical Stock Chart
From Oct 2023 to Oct 2024